Loading clinical trials...
Loading clinical trials...
An Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-914143 in Subject With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-stage Renal Dysfunction
Conditions
Interventions
BMS-914143 (Peginterferon Lambda-1a)
Locations
3
United States
Clinical Pharmacology Of Miami Inc.
Miami, Florida, United States
Orlando Clinical Research Center
Orlando, Florida, United States
New Orleans Center For Clinical Research - Knoxville
Knoxville, Tennessee, United States
Start Date
September 1, 2012
Primary Completion Date
February 1, 2013
Completion Date
February 1, 2013
Last Updated
June 5, 2013
NCT06537414
NCT06491563
NCT07515209
NCT06159062
NCT04391985
NCT04387539
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions